Archives: FRCA Part 1

FCA1-0828

Which among the given choices can be used to describe a persistent and expected level of disease in a particular population?

FCA1-0829

Which among the following is not true regarding disease rates?

FCA1-0830

A doctor has recorded the number of times the patient did not attend (DNA) the clinic for a study over a 10 month period. Number of DNAs in 10 Months: 1st Month: 0, 2nd Month: 3, 3rd Month: 1, 4th Month: 45, 5th Month: 2, 6th Month: 0, 7th Month: 1, 8th Month: 4, 9th Month: 4, 10th Month: 2. Which among the following is the most apt way of summarizing mean value?

FCA1-0831

A chain smoker is interested in knowing how many years of his life would be lessened by smoking. You tell him explicitly that precise determination is impossible but you can tell him the proportion of people who died due to smoking. Which of the following epidemiological term is apt in this regard?

FCA1-0832

Among the following options which one compares variance within the group and variance between groups?

FCA1-0833

Among the following which one is not a criterion for the assessment of causality?

FCA1-0809

A medical student performed a case control study for her final dissertation. It involved examining marijuana exposure in a group of patients with and without COPD. What form of bias is the study most susceptible to?

FCA1-0810

The prospects of setting up a health facility to help patients with ischaemic heart disease in a remote area are under consideration and you have been asked to look into it. What’s the crucial factor in finding out the amount of resources needed to go ahead with the idea?

FCA1-0812

During 2015 it was reported in the New England Journal of Medicine that the usage of empagliflozin(a sodium-glucose-co-transporter 2 inhibitor) caused a decrease in the cardiovascular deaths, non fatal heart attacks and strokes in patients suffering from type 2 diabetes. The results were published per 1000 patient years. With the above mentioned drug, the event rate turned out to be 37.3/1000 patient years whereas the placebo had an event rate of 43.9/1000 patient years. How many further patients need to be treated with empagliflozin to avoid any further incidence of cardiovascular death or non fatal myocardial infraction and non fatal stroke?

FCA1-0813

Among the following options, which one can not be the value of Pearson’s correlation coefficient?